Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1997 1
1999 2
2001 2
2003 2
2006 2
2007 1
2008 5
2009 3
2010 5
2011 4
2012 6
2013 9
2014 8
2015 6
2016 13
2017 12
2018 12
2019 14
2020 14
2021 14
2022 5
2023 3
2024 17
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Dasari A, et al. JAMA Oncol. 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589. JAMA Oncol. 2017. PMID: 28448665 Free PMC article.
IMPORTANCE: The incidence and prevalence of neuroendocrine tumors (NETs) are thought to be rising, but updated epidemiologic data are lacking. OBJECTIVE: To explore the evolving epidemiology and investigate the effect of therapeutic advances on …
IMPORTANCE: The incidence and prevalence of neuroendocrine tumors (NETs) are thought to be rising, but updated e …
Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, Luo F. Xu Z, et al. JAMA Netw Open. 2021 Sep 1;4(9):e2124750. doi: 10.1001/jamanetworkopen.2021.24750. JAMA Netw Open. 2021. PMID: 34554237 Free PMC article.
IMPORTANCE: Although the incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have been thought to have increased during the past decades, updated epidemiologic and survival data are lacking. ...Statistical analysi …
IMPORTANCE: Although the incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) hav …
Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States.
Shah S, Gosain R, Groman A, Gosain R, Dasari A, Halfdanarson TR, Mukherjee S. Shah S, et al. Cancers (Basel). 2021 Apr 7;13(8):1753. doi: 10.3390/cancers13081753. Cancers (Basel). 2021. PMID: 33916960 Free PMC article.
BACKGROUND: The incidence and prevalence of neuroendocrine neoplasms (NENs) are rapidly rising. Epidemiologic trends have been reported for common NENs, but specific data for lung NENs are lacking. METHODS: We conducted a retrospective analysis utilizi …
BACKGROUND: The incidence and prevalence of neuroendocrine neoplasms (NENs) are rapidly rising. Epidemiologic trends …
Racial Differences in Gastroenteropancreatic Neuroendocrine Tumor Treatment and Survival in the United States.
Kessel E, Naparst M, Alpert N, Diaz K, Ahn E, Wolin E, Taioli E, Kim MK. Kessel E, et al. Pancreas. 2021 Jan 1;50(1):29-36. doi: 10.1097/MPA.0000000000001707. Pancreas. 2021. PMID: 33370020
OBJECTIVES: The objective of this study was to evaluate racial differences in cancer treatment and survival in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. METHODS: Using the Surveillance, Epidemiology, and End Results Registry, we i …
OBJECTIVES: The objective of this study was to evaluate racial differences in cancer treatment and survival in gastroenteropancreatic …
Management and outcomes of primary anorectal melanoma in the United States.
Menon H, Patel RR, Cushman TR, Amini A, Seyedin SN, Adams AC, Lin C, Verma V. Menon H, et al. Future Oncol. 2020 Mar;16(8):329-338. doi: 10.2217/fon-2019-0715. Epub 2020 Feb 18. Future Oncol. 2020. PMID: 32067486
No OS benefit was seen with chemotherapy (p = 0.16), radiotherapy (p = 0.31) or adjuvant therapy post surgery (p > 0.05 for all groups). Targeted therapy trended toward higher survival in metastatic patients (1.33 vs 0.55 years; p = 0.06). Conclusion: In n …
No OS benefit was seen with chemotherapy (p = 0.16), radiotherapy (p = 0.31) or adjuvant therapy post surgery (p > 0.05 for all groups). …
Mortality and in-patient outcomes in pheochromocytoma patients with hypertensive emergency in the United States: A propensity score matched analysis.
Roth MA, Leyba K, Garg I, Madrid WH, Quazi MA, Sohail AH, Khan R, Sultan S, Sheikh AB. Roth MA, et al. Curr Probl Cardiol. 2024 Jul;49(7):102578. doi: 10.1016/j.cpcardiol.2024.102578. Epub 2024 Apr 22. Curr Probl Cardiol. 2024. PMID: 38657719 Review.
The objective of this analysis was to compare the clinical characteristics, comorbidities, and in-hospital outcomes of patients admitted with hypertensive emergencies with and without co-existing pheochromocytoma. ...We compared demographics, comorbidities, in-hospi …
The objective of this analysis was to compare the clinical characteristics, comorbidities, and in-hospital outcomes of patients …
Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis.
Shafqat H, Ali S, Salhab M, Olszewski AJ. Shafqat H, et al. Dis Colon Rectum. 2015 Mar;58(3):294-303. doi: 10.1097/DCR.0000000000000298. Dis Colon Rectum. 2015. PMID: 25664707
OBJECTIVE: The purpose of this work was to describe the incidence, management, and outcomes of neuroendocrine carcinoma in comparison with high-grade adenocarcinoma. ...INTERVENTIONS: Resection of the primary tumor was the main intervention. MAIN OUTCOME …
OBJECTIVE: The purpose of this work was to describe the incidence, management, and outcomes of neuroendocrine carcinoma …
Malignant neuroendocrine tumors: incidence and outcomes in pediatric patients.
Allan B, Davis J, Perez E, Lew J, Sola J. Allan B, et al. Eur J Pediatr Surg. 2013 Oct;23(5):394-9. doi: 10.1055/s-0033-1333643. Epub 2013 Feb 26. Eur J Pediatr Surg. 2013. PMID: 23444065
INTRODUCTION: Malignant neuroendocrine tumors (NETs) are rare solid tumors infrequently seen in children. This study examines current incidence trends and outcomes for children with NETs. ...RESULTS: Overall, 481 patients were iden …
INTRODUCTION: Malignant neuroendocrine tumors (NETs) are rare solid tumors infrequently seen in children. This study ex …
Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study.
Gosain R, Ball S, Rana N, Groman A, Gage-Bouchard E, Dasari A, Mukherjee S. Gosain R, et al. Cancer. 2020 Feb 15;126(4):792-799. doi: 10.1002/cncr.32607. Epub 2019 Nov 12. Cancer. 2020. PMID: 31714595 Free PMC article.
BACKGROUND: The incidence of neuroendocrine tumors (NETs) is rapidly rising. There are very few studies investigating the role of sociodemographic factors in NETs. ...In the multivariable model, RA patients had a trend toward poorer OS (hazard r …
BACKGROUND: The incidence of neuroendocrine tumors (NETs) is rapidly rising. There are very few studies investigating t …
Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Kipnis ST, Hung M, Kumar S, Heckert JM, Lee H, Bennett B, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Eads JR, Katona BW. Kipnis ST, et al. JAMA Netw Open. 2021 Mar 1;4(3):e212274. doi: 10.1001/jamanetworkopen.2021.2274. JAMA Netw Open. 2021. PMID: 33755166 Free PMC article.
IMPORTANCE: Peptide receptor radionuclide therapy (PRRT) is approved in the US for treatment of gastroenteropancreatic neuroendocrine tumors (NETs), but data on PRRT outcomes within US populations remain scarce. ...At least 1 grade 2 or greater toxic effect w …
IMPORTANCE: Peptide receptor radionuclide therapy (PRRT) is approved in the US for treatment of gastroenteropancreatic neuroendocrine …
137 results